BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35837707)

  • 21. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
    Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
    PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
    Toda Y; Kohashi K; Yamamoto H; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kiyozawa D; Takamatsu D; Kinoshita I; Yamada Y; Maehara J; Kimura A; Tamiya S; Taguchi K; Matsunobu T; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    Sci Rep; 2021 Jul; 11(1):14821. PubMed ID: 34285260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
    Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
    Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report.
    Law GW; Yeo NEM; Howe TS; Tan YZ; Tan SB; Siddiqui MMA
    Spine (Phila Pa 1976); 2018 May; 43(9):E551-E556. PubMed ID: 29016442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
    Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
    Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS; Hindiskere S; Doddarangappa S; Pal U
    Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
    Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
    J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
    Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symplastic/pseudoanaplastic giant cell tumor of the bone.
    Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
    Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative denosumab treatment in patients with giant cell bone tumors in limbs: A retrospective study using propensity score matching.
    Huang Y; Xu M; Wang B; Zhao Z; Lin T; Huang G; Yin J; Xie X; Shen J; Zou C
    Cancer Med; 2023 Jun; 12(11):12041-12049. PubMed ID: 37212474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
    Tang Q; Lu J; Zhu X; Song G; Wu H; Xu H; Wang A; Wang J
    Eur Spine J; 2023 Dec; 32(12):4297-4305. PubMed ID: 37318598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.